Earnings summaries and quarterly performance for KEWAUNEE SCIENTIFIC CORP /DE/.
Executive leadership at KEWAUNEE SCIENTIFIC CORP /DE/.
Board of directors at KEWAUNEE SCIENTIFIC CORP /DE/.
Research analysts covering KEWAUNEE SCIENTIFIC CORP /DE/.
Recent press releases and 8-K filings for KEQU.
Kewaunee Scientific Reports Q2 2026 Financial Results
KEQU
Earnings
M&A
New Projects/Investments
- Kewaunee Scientific Corporation reported sales of $70,096,000 for the second quarter of fiscal year 2026, marking a 46.8% increase compared to the prior year's second quarter.
- Diluted earnings per share were $0.82, a decrease from $1.01 in the prior year quarter, while EBITDA increased to $5,790,000 from $4,883,000 in the same period last year.
- The company's order backlog was $192.9 million on October 31, 2025, an increase from $184.4 million on October 31, 2024.
- The debt-to-equity ratio improved to 0.88-to-1 on October 31, 2025, compared to 0.99-to-1 on April 30, 2025.
- Management expects continued volatility in project delivery timelines for the balance of the fiscal year, but strong quoting and booking activity, along with the performance of the newly acquired Nu Aire, Inc., are expected to support future growth.
Dec 10, 2025, 9:09 PM
Kewaunee Scientific Reports Q2 FY2026 Results
KEQU
Earnings
Revenue Acceleration/Inflection
M&A
- Kewaunee Scientific Corporation reported second quarter fiscal year 2026 sales of $70,096,000, marking a 46.8% increase compared to the prior year's second quarter.
- Net earnings decreased to $2,445,000 and diluted earnings per share were $0.82 for the quarter, down from $3,008,000 and $1.01 respectively in the prior year.
- The company's order backlog was $192.9 million as of October 31, 2025, an increase from $184.4 million a year prior, but a decrease from $214.6 million on April 30, 2025.
- Cash on hand was $13,679,000 and working capital was $67,830,000 on October 31, 2025, with the debt-to-equity ratio improving to 0.88-to-1 from 0.99-to-1 on April 30, 2025.
- Domestic segment sales increased by 51.7% to $55,224,000, while International sales grew by 31.0% to $14,872,000, with the strong performance of the newly acquired Nu Aire, Inc. helping to offset volatility in the legacy business.
Dec 10, 2025, 9:02 PM
Kewaunee Scientific Announces Debt Refinancing and Seller Note Repayment
KEQU
Debt Issuance
M&A
- Kewaunee Scientific Corporation (KEQU) announced the successful debt refinancing and full repayment of its Seller Notes on December 4, 2025.
- The Seller Notes, which originated from the acquisition of Nu Aire, Inc., had an original outstanding principal balance of $23.0 million and were repaid ahead of their November 1, 2027 maturity date.
- The repayment was partially funded by an amendment with PNC Bank, National Association, which provided an additional $10.0 million term loan, and by drawing available funds under the company's revolving line of credit.
- This transaction is expected to lower the overall debt load, reduce the effective interest rate on its debt portfolio, and materially decrease expected future interest expense.
Dec 4, 2025, 9:59 PM
Kewaunee Scientific Refinances Debt and Repays Seller Notes
KEQU
Debt Issuance
M&A
- Kewaunee Scientific Corporation successfully refinanced its debt and fully repaid $23.0 million in Seller Notes on December 4, 2025, ahead of their November 1, 2027, maturity date.
- This repayment was partially funded by an amendment with PNC Bank, which included an additional $10.0 million term loan and the use of available funds from its revolving line of credit.
- The company expects this action to lower its overall debt load, reduce the effective interest rate, and materially decrease future interest expense.
- The early repayment was attributed to the consistent financial performance of its legacy business, the accretive financial contribution from the Nu Aire business (which the Seller Notes were connected to), and disciplined cash management.
Dec 4, 2025, 9:55 PM
KEQU Reports Fiscal Year 2025 Financial Results and Discusses Nu Aire Acquisition
KEQU
Earnings
M&A
Revenue Acceleration/Inflection
- Kewaunee Scientific Corporation reported sales of $240.5 million for fiscal year 2025, an 18.0% increase compared to $203.8 million in the prior year.
- The company's diluted earnings per share for fiscal year 2025 were $3.83, compared to $6.38 in the prior fiscal year, while adjusted diluted earnings per share increased to $5.37 from $4.19.
- Kewaunee successfully completed the acquisition of Nu Aire, Inc. on November 1, 2024, which expanded its product offerings and market presence.
- The company's order backlog was $214.6 million on April 30, 2025, an increase from $155.6 million on April 30, 2024.
Aug 27, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more